CASEIN KINASE 1 INHIBITORS FOR THE TREATMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA

BRYJA, Vítězslav, Markéta KAUCKÁ, Karla PLEVOVÁ, Šárka PAVLOVÁ, Šárka POSPÍŠILOVÁ and Alois KOZUBÍK. CASEIN KINASE 1 INHIBITORS FOR THE TREATMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA. 2016.

Basic information

• Original name: CASEIN KINASE 1 INHIBITORS FOR THE TREATMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
• Authors: BRYJA, Vítězslav (203 Czech Republic, guarantor, belonging to the institution), Markéta KAUCKÁ (203 Czech Republic, belonging to the institution), Karla PLEVOVÁ (203 Czech Republic, belonging to the institution), Šárka PAVLOVÁ (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution) and Alois KOZUBÍK (203 Czech Republic, belonging to the institution).
• Edition: Number: EP2882437 (B1), Publisher: European patent Office, Place of publication: Mnichov, Owner's name: MASARYKOVA UNIVERZITA, 2016.

Other information

• Original language: English
• Type of outcome: Patent
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: Germany
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• RIV identification code: RIV/00216224:14740/16:00088788
• Organization unit: Central European Institute of Technology
• Keywords in English: casein kinase 1; lymphocytic leukemia; B-cell
• Tags: rivok

Abstract

The invention relates to inhibitors of casein kinase 1 for use in the treatment of B-cell chronic lymphocytic leukemia.

Links

• GAP301/11/0747, research and development project: Name: Molekulární mechanismy nekanonické Wnt signalizace v leukémii

Investor: Czech Science Foundation

• MSM0021622430, plan (intention): Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies

• NT11217, research and development project: Name: Úloha nekanonické Wnt signalizace v molekulární patogenezi chronické lymfocytární leukémie